The unit, Optum Rx, will move eight products, including all short- and rapid-acting insulin, to tier one, or preferred status, which offers the lowest price for consumers and is effective Jan. 1. Eli Lilly, Novo Nordisk and Sanofi will have their insulin products added to the preferred status.
Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt obligations, to facilitate growth Q3/22 Net revenues of $17.6.
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:.